Lipocine Inc. (NASDAQ:LPCN) – Equities research analysts at Roth Capital lifted their FY2018 earnings estimates for shares of Lipocine in a research report issued to clients and investors on Monday. Roth Capital analyst M. Higgins now anticipates that the firm will post earnings per share of $2.52 for the year, up from their prior forecast of $2.50.
Several other research firms also recently weighed in on LPCN. Canaccord Genuity reiterated a “buy” rating and issued a $6.00 target price (down previously from $15.00) on shares of Lipocine in a research note on Saturday, July 2nd. HC Wainwright started coverage on shares of Lipocine in a research note on Monday. They issued a “buy” rating and a $25.00 target price for the company.
Shares of Lipocine (NASDAQ:LPCN) traded down 1.37% during trading on Tuesday, hitting $3.60. The stock had a trading volume of 431,179 shares. The stock’s market cap is $65.73 million. Lipocine has a one year low of $2.51 and a one year high of $14.80. The stock’s 50-day moving average price is $3.95 and its 200 day moving average price is $6.23.
Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05.
Several institutional investors have recently added to or reduced their stakes in LPCN. California State Teachers Retirement System purchased a new position in Lipocine during the second quarter worth approximately $106,000. BlackRock Investment Management LLC raised its position in Lipocine by 2,370.7% in the second quarter. BlackRock Investment Management LLC now owns 62,707 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 60,169 shares during the period. Landscape Capital Management L.L.C. purchased a new position in Lipocine during the first quarter worth approximately $385,000. DRW Securities LLC purchased a new position in Lipocine during the second quarter worth approximately $443,000. Finally, State Street Corp raised its position in Lipocine by 1,408.9% in the second quarter. State Street Corp now owns 200,679 shares of the specialty pharmaceutical company’s stock worth $609,000 after buying an additional 187,379 shares during the period. Institutional investors own 47.22% of the company’s stock.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.